In Côte d’Ivoire’s evolving healthcare landscape, Assane Coulibaly has emerged as one of the most influential figures bridging pharmaceutical manufacturing, regulatory governance, and regional policy coordination. As head of the Ivorian Pharmaceutical Regulatory Authority (AIRP), he sits at the center of efforts to strengthen drug safety, improve industrial standards, and expand local production capacity across a sector increasingly tied to public health and economic sovereignty.

His leadership comes at a time when West Africa is grappling with structural dependence on imported medicines, uneven regulatory capacity, and rising demand for safe and affordable healthcare products. Within this context, Coulibaly’s profile stands out for a rare combination of factory-level experience and high-level regulatory authority.

Building a career across the pharmaceutical value chain

Coulibaly is a Doctor of Pharmacy, specialized in Industrial Pharmacy since 1991, with more than three decades of experience across pharmaceutical production, distribution, and regulation. He was trained at the University of Rouen between 1982 and 1990, where he developed a foundation in pharmaceutical sciences anchored in industrial systems and production realities.

Unlike many regulators who enter public service through administrative pathways, Coulibaly’s career was built inside the operational core of the pharmaceutical industry. He also previously owned a pharmacy, giving him early exposure to the distribution side of the pharmaceutical value chain and to the realities of access to medicine at the retail level.

His most extensive industrial experience came at Cipharm, where he spent over two decades progressing through senior leadership roles. He served as production manager, production and logistics manager, industrial director, supply chain director, deputy general manager, and ultimately operations director.

This progression placed him at the center of manufacturing systems responsible for ensuring drug quality, batch stability, compliance with production standards, workforce coordination, and supply chain reliability. It is this long immersion in industrial operations that shaped his later regulatory philosophy: that pharmaceutical quality is not defined by policy alone, but by disciplined execution across the entire production chain.

From industry leadership to regional influence

Beyond corporate roles, Coulibaly became a central figure in West Africa’s pharmaceutical industry governance.

He served as President of the Association of Pharmaceutical Producers of Côte d’Ivoire (APPCI) from 2012 to 2019, where he played a key role in promoting local pharmaceutical production, strengthening engagement between manufacturers and government institutions, and advocating for improved access to quality generic medicines.

His tenure reflected a broader strategic push: building domestic manufacturing capacity as a pathway to healthcare resilience and reduced dependence on external supply chains.

At the regional level, he served as Vice-President of the West African Pharmaceutical Manufacturers Association (WAPMA) from 2012 to 2016 and remains a Permanent Member of its Executive Committee under the ECOWAS framework. In this role, he contributed to regional coordination efforts aimed at harmonizing pharmaceutical policies and strengthening industrial collaboration across West Africa.

Between 2017 and 2020, he also served as lead regional coordinator for the ECOWAS Good Manufacturing Practices (GMP) roadmap project in partnership with UNIDO. The initiative focused on aligning pharmaceutical production standards across the region with internationally recognized GMP requirements, a critical step in improving both product quality and cross-border trade acceptance.

Assane Coulibaly’s regulatory leadership at AIRP

Since February 2020, Coulibaly has headed the Ivorian Pharmaceutical Regulatory Authority (AIRP), a strategic institution responsible for coordinating the national regulatory system for medicines and health products.

His mandate extends beyond administrative oversight of approvals and certifications. It encompasses market credibility, patient safety, operator discipline, and the broader ability of Côte d’Ivoire to develop a competitive pharmaceutical industry.

What distinguishes his leadership is the dual perspective he brings. Having spent decades inside pharmaceutical manufacturing, he understands both sides of regulation: the constraints faced by producers and the risks posed to populations when oversight is weak or inconsistent.

This background has shaped a regulatory approach that treats regulation not as a barrier to industry, but as an enabling structure for trust, quality assurance, and long-term sector development.

Assane Coulibaly’s international engagement and professional recognition

Beyond his national role, Coulibaly serves as a consultant to international organizations, focusing on the promotion of Good Pharmaceutical Practices across the full value chain. He is also a frequent speaker on issues such as counterfeit medicine control, regulatory strengthening, and regional pharmaceutical integration.

His contributions to the sector were formally recognized in 2022 when he received the French Academic Prize in Pharmacy, an award honoring professional excellence and impact in pharmaceutical advancement.

Assane Coulibaly’s strategy anchored in sovereignty, quality, and integration

Coulibaly’s vision for the pharmaceutical sector is structured around three interconnected priorities: strengthening regional value chains, harmonizing Good Pharmaceutical Practices in line with international standards, and expanding local and regional production of safe and affordable medicines.

He has consistently emphasized that pharmaceuticals should be understood not only as a health sector, but as a strategic industry tied to economic development, industrial policy, logistics infrastructure, and national security.

This perspective places him at the centre of West Africa’s ongoing debate on pharmaceutical sovereignty, in which governments are increasingly seeking to reduce import dependence and improve domestic production capacity.

Assane Coulibaly: Strengthening institutional resilience for the next phase of growth

Under Coulibaly’s leadership, AIRP continues to operate at the intersection of regulation, industrial policy, and public health protection. The institution’s role is increasingly tied to ensuring that pharmaceutical markets are not only compliant, but also capable of supporting sustainable industrial growth.

His career reflects a broader institutional shift in Côte d’Ivoire’s pharmaceutical sector: from fragmented oversight to system-based regulation anchored in technical expertise and industrial understanding.

As West Africa’s healthcare systems continue to expand, Coulibaly’s trajectory reflects a larger transformation underway in the region’s pharmaceutical ecosystem, one where regulation, manufacturing, and regional integration are becoming inseparable pillars of long-term health security.